News & Events zu Vyne Therapeutics Inc (VYNE)VYNEVyne Therapeutics Inc

Yarrow Bioscience Completes Merger with VYNE and Financing of $200M

Yarrow Bioscience announced the completion of its merger with VYNE Therapeutics and the previously announced private financings totaling approximately $200M. The combined company will operate as Yarrow Bioscience, Inc., with its shares expected to begin trading on the Nasdaq Capital Market on Tuesday, July 28, under the ticker symbol "YARW." Yarrow's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor monoclonal antibody designed to directly disrupt the central mechanism of both GD and TED, offering a single targeted treatment to address both diseases. By blocking TSHR, the common target of autoantibodies in both the thyroid and the eye, YB-101 has the potential to rapidly arrest the disease process and provide improved efficacy and safety versus the current standard of care and other mechanisms in development. YB-101 is designed for convenient subcutaneous administration, with the potential for infrequent dosing and future autoinjector presentation. The Company has initiated dosing in a Phase 2a/2b trial evaluating YB-101 in patients with GD, with or without concurrent TED, and the molecule has received Fast Track Designation from the U.S. Food and Drug Administration. Data from the Phase 2a portion of the trial are expected in the second half of 2027. The Company's licensing partner, Changchun GeneScience Pharmaceutical, is currently developing YB-101, also known as GenSci-098, for the treatment of GD and TED in China. YB-101 is currently being evaluated by GenSci in an ongoing Phase 1 single ascending dose and MAD trial in patients with TED and a Phase 1 SAD trial in patients with GD in China. In the SAD portion of the TED trial, YB-101 demonstrated a rapid, dose-dependent proof-of-mechanism and showed evidence of clinical responses in TED with a favorable safety profile. There were no clinically meaningful safety differences versus placebo in the SAD. These safety data supported the initiation of the MAD portion of the trial in China, as well as the initiation of the Company's Phase 2a/2b trial in patients with GD. Data from the MAD portion of GenSci's Phase 1 TED trial are anticipated in the second half of 2027 and will inform future development plans for YB-101 in TED globally. As previously announced, Yarrow completed pre-closing private placements that resulted in total gross proceeds of approximately $200M. The financings were led by founding investor RTW Investments, with participation from OrbiMed, Janus Henderson Investors, venBio Partners, Logos Capital, LifeSci Venture Partners, and Perceptive Advisors. Yarrow's cash balance is expected to support the Company's operations into 2028. Pursuant to the terms of the previously disclosed merger agreement, each outstanding share of Yarrow common stock was converted into 0.7171 shares of common stock of the combined company, as adjusted for the reverse stock split of VYNE common stock at a ratio of 1-for-50 shares, effected on July 24, 2026. In the reverse stock split, every 50 shares of VYNE common stock outstanding were combined and reclassified into 1 share of VYNE common stock. The new CUSIP number for the combined company following the reverse stock split and merger is 92941V407. In addition, on July 23, 2026, VYNE distributed its previously announced special cash dividend in an aggregate amount of $17.3M, or an estimated $0.40242 per share to VYNE's stockholders and warrant holders of record as of July 22, 2026, based on their holdings as of that date, subject to the Nasdaq due bill procedures as previously disclosed. The previously announced special cash dividend was not affected by the reverse stock split. The per share dividend is based on 42,989,506 shares of VYNE common stock and common stock equivalents outstanding as of July 22, 2026. Following the completion of the reverse stock split and merger, the combined company's total issued and outstanding common stock is approximately 2.8M shares, or approximately 33.6M shares on a fully-diluted basis, or approximately 28.6M shares excluding shares underlying equity plans and awards.

VYNE Therapeutics Approves 1-for-50 Reverse Stock Split

VYNE Therapeutics announced that its board of directors has approved a reverse stock split of VYNE's common stock at a ratio of 1-for-50 in connection with the anticipated closing of the proposed merger with Yarrow Bioscience. The reverse stock split was previously approved by VYNE's stockholders at VYNE's special meeting in lieu of the annual meeting of stockholders held on July 16. Following the merger, the combined company's common stock is expected to begin trading on a post-reverse stock split basis on Nasdaq on July 27, under the new name "Yarrow Bioscience, Inc."

VYNE Therapeutics Declares Special Cash Dividend of $16.5 Million

VYNE Therapeutics announced that its board of directors has declared a special cash dividend in connection with the previously announced merger with Yarrow Bioscience, pursuant to the agreement and plan of merger and reorganization, dated December 17, 2025. The cash dividend, which VYNE estimates will be an aggregate of $16.5M, or an estimated 38c per share, will be payable in cash to the stockholders and warrant holders of record as of July 22. The estimated per share dividend is based on 42,989,506 shares of common stock and common stock equivalents outstanding as of July 9. The total actual distribution of the amount of the cash dividend is scheduled to be paid to VYNE's transfer agent, in accordance with the merger agreement, on July 23, and may be higher or lower than the estimated amount. The transfer agent will distribute the cash dividend to stockholders and warrant holders within a few days following the dividend payment date. Payment of the cash dividend is conditioned upon the closing of the merger. Closing is expected to occur on or about July 24, assuming that the transaction is approved by the company's stockholders and the satisfaction or waiver of all conditions under the merger agreement. The company's stockholders will consider and vote upon approval of the merger at the special meeting of the company's stockholders scheduled for 10:00 a.m. Eastern Time on July 16.